We read with great interest a meta-analysis by Jaffery et al. [1] of randomized control trials (RCTs) comparing minimally invasive direct coronary artery bypass (MIDCAB) versus percutaneous coronary stenting (PCS) for stenosis of the proximal left anterior descending artery (LAD). Between PCS and MIDCAB, there was no difference in major adverse cardiac events (MACE), i.e. the composite end point of mortality, myocardial infarction, and target vessel revascularization: relative risk (RR) (95% confidence interval In conclusion, our meta-analysis of currently available RCTs showed that PCS was fraught with significantly increased risk of MACE in comparison to MIDCAB even including the trial with DES.
We thank Takagi and colleagues [1] for their comments and for pointing out one additional study along with the updated version of the articles by Drenth et al. and Ciwoski et al. We could not include the updated version of the article by Cisowski et al. as it was not in English language.
We have reanalyzed the data using the additional information. Unlike the analysis done by Takagi and colleagues, our updated analysis however does not show a significant difference favoring minimally invasive direct coronary artery bypass (MIDCAB) for the hard end-points of mortality, relative risk (RR) = 0.81 (95% CI: 0.42, 1.57), p = 0.53, I 2 = 0% and for the end points of mortality plus myocardial infarction, RR = 0.92 (95% CI: 0.56, 1.50), p = 0.72, I 2 = 0%. For the composite endpoint of mortality, myocardial infarction and target vessel revascularization, there was a non-statistical trend in favor of MIDCAB, RR = 1.76 (95% CI: 0.96, 3.25), p = 0.07, I 2 = 54%. Therefore, it is quite clear that the small advantage of MIDCAB over stenting is by lowering repeat target vessel revascularizations. This is not unexpected and most likely driven by the 20-30% restenosis risk of bare metal stents
